Literature DB >> 11889075

Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells.

J M Silva1, R Rodriguez, J M Garcia, C Muñoz, J Silva, G Dominguez, M Provencio, P España, F Bonilla.   

Abstract

BACKGROUND: Although circulating tumour DNA has been detected in patients with different types of cancer, little is known of free RNA in cancer patients. AIMS: We investigated the presence of RNA from epithelial tumours in plasma from patients with colorectal carcinomas, and its correlation with tumour characteristics and circulating tumour cells.
METHODS: beta-actin mRNA was analysed to assess the viability of plasma RNA in samples from 53 patients with colonic cancer and 25 controls. Subsequently, nested primers were used to detect the presence of cytokeratin 19 (CK19) and carcinoembryonic antigen (CEA) RNA in the same samples. Nine clinicopathological parameters were studied to correlate the molecular and clinical parameters. Additionally, we investigated for micrometastases in blood in 18 of these patients and in 10 of the controls samples.
RESULTS: All samples had detectable quantities of beta-actin RNA. In the controls, one case (4%) was positive for CEA and five (20%) for CK19 RNA; of the 53 patients, 17 cases (32%) were positive for CEA and 39 (73.6%) for CK19 RNA. This was statistically significant (p=0.000001). Advanced stages (p=0.03) and soluble CEA status (p=0.03) were associated with the presence of CEA, CK19, or both RNAs in plasma. Lymph node metastases (p=0.06) and vascular invasion (p=0.07) were almost significant. On the basis of these results, we examined the possible presence of micrometastases in blood in several of these patients. The presence of plasma tumour RNA was found to be associated with circulating tumour cells in blood (p=0.04).
CONCLUSIONS: Epithelial tumour RNA is detectable in plasma from colon cancer patients. This molecular event is associated with advanced stages and circulating tumour cells. Our results could offer new approaches in the diagnosis and monitoring of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889075      PMCID: PMC1773179          DOI: 10.1136/gut.50.4.530

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

Review 1.  Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients.

Authors:  P Anker; H Mulcahy; X Q Chen; M Stroun
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

2.  Carcinoembryonic antigenic activity of tissue extracts: a quantitative study of malignant and benign neoplasms, cirrhotic liver, normal adult and fetal organs.

Authors:  S K Khoo; N L Warner; J T Lie; I R Mackay
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

3.  Actions of cis-diamminedichloroplatinum on cell surface nucleic acids in cancer cells as determined by cell electrophoresis techniques.

Authors:  D A Juckett; B Rosenberg
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

4.  Telomerase RNA as a detection marker in the serum of breast cancer patients.

Authors:  X Q Chen; H Bonnefoi; M F Pelte; J Lyautey; C Lederrey; S Movarekhi; P Schaeffer; H E Mulcahy; P Meyer; M Stroun; P Anker
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

Review 5.  Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.

Authors:  I J Diel; R J Cote
Journal:  Cancer Treat Rev       Date:  2000-02       Impact factor: 12.111

6.  Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans.

Authors:  A J Wieczorek; C Rhyner; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.

Authors:  M S Kopreski; F A Benko; D J Borys; A Khan; T J McGarrity; C D Gocke
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

8.  Circulating membrane vesicles in leukemic blood.

Authors:  J M Carr; A M Dvorak; H F Dvorak
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

9.  An "external" RNA removable from mammalian cells by mild proteolysis.

Authors:  M Rieber; J Bacalao
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

10.  Elevated serum ribonuclease in patients with pancreatic cancer.

Authors:  K K Reddi; J F Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

View more
  41 in total

Review 1.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung cancer.

Authors:  Akemi Sato; Naoko Sueoka-Aragane; Juichi Saitoh; Kazutoshi Komiya; Takashi Hisatomi; Rika Tomimasu; Shinichiro Hayashi; Eisaburo Sueoka
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-07       Impact factor: 4.553

3.  Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients.

Authors:  Reza Raeisossadati; Moein Farshchian; Azita Ganji; Alieza Tavassoli; Arash Velayati; Ezzat Dadkhah; Somaye Chavoshi; Mostafa Mehrabi Bahar; Bahram Memar; Mohammad Taghi Rajabi Mashhadi; Hossein Naseh; Mohammad Mahdi Forghanifard; Meysam Moghbeli; Omeed Moaven; Mohammad Reza Abbaszadegan
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

4.  Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched.

Authors:  José Miguel García; Vanesa García; Cristina Peña; Gemma Domínguez; Javier Silva; Raquel Diaz; Pablo Espinosa; Maria Jesús Citores; Manuel Collado; Félix Bonilla
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

5.  EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages.

Authors:  N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

6.  Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy.

Authors:  Chun-Chao Chang; Shung-Haur Yang; Chih-Cheng Chien; Shu-Hung Chen; Shiann Pan; Chia-Long Lee; Chih-Ming Lin; Hsiao-Lun Sun; Chi-Cheng Huang; Yih-Yiing Wu; Ruey-Neng Yang; Chi-Jung Huang
Journal:  BMC Cancer       Date:  2009-10-22       Impact factor: 4.430

Review 7.  Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review.

Authors:  G Peach; C Kim; E Zacharakis; S Purkayastha; P Ziprin
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

8.  Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Authors:  Juan Wei; Lian-Ke Liu; Wen Gao; Cheng-Jun Zhu; Yi-Qian Liu; Ting Cheng; Yong-Qian Shu
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

Review 9.  Circulating RNAs as new biomarkers for detecting pancreatic cancer.

Authors:  Takahiro Kishikawa; Motoyuki Otsuka; Motoko Ohno; Takeshi Yoshikawa; Akemi Takata; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

10.  Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications.

Authors:  Vanesa Garcia; Jose Miguel Garcia; Javier Silva; Paloma Martin; Cristina Peña; Gemma Dominguez; Raquel Diaz; Mercedes Herrera; Constanza Maximiano; Pilar Sabin; Antonio Rueda; Miguel Angel Cruz; Jose Rodriguez; Miguel Angel Canales; Felix Bonilla; Mariano Provencio
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.